Earendil Labs, an AI-driven biotechnology company advancing next-generation biologics, today announced the first patient has been dosed in a Phase IIa clinical trial of HXN-1001, a half-life extended ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results